Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15602
Abstract: Ravulizumab is an expensive complement C5âinhibitor for the treatment of paroxysmal nocturnal haemoglobinuria. Recently, a subcutaneous formulation has entered the market, for which the approved dosing regimen results in supratherapeutic ravulizumab concentrations in the majority… read more here.
Keywords: subcutaneous ravulizumab; dose optimalization; patient friendliness; ravulizumab ... See more keywords